NRXS Stock Overview
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
NeurAxis, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.00 |
| 52 Week High | US$6.93 |
| 52 Week Low | US$1.80 |
| Beta | 0 |
| 1 Month Change | -8.32% |
| 3 Month Change | 27.12% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -50.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| NRXS | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -7.7% | 1.6% | 1.0% |
| 1Y | n/a | -1.4% | 21.9% |
Return vs Industry: Insufficient data to determine how NRXS performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how NRXS performed against the US Market.
Price Volatility
| NRXS volatility | |
|---|---|
| NRXS Average Weekly Movement | 13.5% |
| Medical Equipment Industry Average Movement | 7.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NRXS's share price has been volatile over the past 3 months.
Volatility Over Time: NRXS's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 19 | Brian Carrico | neuraxis.com |
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics.
NeurAxis, Inc. Fundamentals Summary
| NRXS fundamental statistics | |
|---|---|
| Market cap | US$19.78m |
| Earnings (TTM) | -US$14.63m |
| Revenue (TTM) | US$2.46m |
8.0x
P/S Ratio-1.4x
P/E RatioIs NRXS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NRXS income statement (TTM) | |
|---|---|
| Revenue | US$2.46m |
| Cost of Revenue | US$303.35k |
| Gross Profit | US$2.16m |
| Other Expenses | US$16.78m |
| Earnings | -US$14.63m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.22 |
| Gross Margin | 87.67% |
| Net Profit Margin | -594.57% |
| Debt/Equity Ratio | -10.6% |
How did NRXS perform over the long term?
See historical performance and comparison